Clinical trials
Breast Cancer Screening and Diagnosis clinical trials
Below are recruiting breast cancer screening and diagnosis clinical trials, each written for real people, not researchers. We’re tracking 245 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT04038619RecruitingPhase 1
Fecal transplant for immune-therapy diarrhea or bowel inflammation
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
Houston, TexasAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT02732171Recruiting
Blood and bone marrow tests to track breast cancer return
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02620852Recruiting
Wisdom Study: Women’s breast cancer screening decisions
This study looks at how to decide the best breast cancer screening (like mammograms) based on your personal risk. It may help by testing a smarter way to match screening to your risk level.
Birmingham, AlabamaAges 30–74 - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT06404697RecruitingPhase 2
Extra radiation to lymph nodes above collarbone for high-risk breast cancer
This trial tests giving a focused, higher dose of radiation to the lymph nodes above the collarbone after breast cancer treatment. It is for patients whose cancer did not fully disappear from those nodes after pre-surgery chemotherapy, to see if extra radiation can help prevent recurrence.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04990921RecruitingPhase 2
Palliative radiation plus pembrolizumab for metastatic breast cancer
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Louisville, KentuckyAges 18 years+ - NCT06508307RecruitingPhase 1
A study of an injected virus for advanced solid tumors
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Zhengzhou, HenanAges 18–75 - NCT06545045Recruiting
Thinking and memory help after breast cancer treatment
This trial tests a cognitive rehabilitation program for breast cancer survivors who have ongoing problems with thinking, memory, or concentration after finishing treatment. The goal is to help improve daily mental function.
Columbia, MissouriAges 20–75 - NCT05827081RecruitingPhase 3
Ribociclib plus endocrine therapy for early breast cancer
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
Birmingham, AlabamaAges 18–100 - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05035836RecruitingPhase 2
Test drug after early HER2-positive breast cancer surgery
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
Houston, TexasAges 18 years+ - NCT02102165Recruiting
Study samples from metastatic triple-negative breast cancer
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
BrusselsAges 18 years+ - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT07072728RecruitingPhase 2
Psilocybin therapy for anxiety in cancer patients
This trial tests whether psilocybin (a psychedelic drug given with talk therapy) can help people with cancer who have adjustment disorder—a condition where a cancer diagnosis causes severe anxiety or stress. It focuses on reducing anxiety and improving emotional well-being.
Abbotsford, VictoriaAges 18–80 - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07108309RecruitingPhase 2
Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
BrestAges 18–74 - NCT04947189RecruitingPhase 1/Phase 2
Seviteronel plus chemo for advanced triple-negative breast cancer
This trial tests seviteronel together with standard chemotherapy to treat certain types of advanced breast cancer that has spread. It’s looking to see how well the combination works and how safe it is, especially for cancers that are androgen-receptor positive.
Darlinghurst, New South WalesAges 18 years+ - NCT06413212Recruiting
Personalized drug test for advanced cancer with fluid buildup
This trial uses a special test on your cancer cells to find which chemotherapy might work best for you. The aim is to treat advanced cancer that has caused fluid buildup in the chest or abdomen.
Wuhan, HubeiAges 18 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06831955RecruitingPhase 2
Lifestyle program to boost chemo before breast cancer surgery
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
AntwerpAges 18 years+
Hear when a new Breast Cancer Screening and Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening and diagnosis?
- Yes. Clin2 currently lists 245 recruiting breast cancer screening and diagnosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening and diagnosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening and diagnosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.